Panther Fusion® Flu A/B/RSV Assay
<!--td {border: 1px solid #cccccc;}br {mso-data-placement:same-cell;}--> A fully-automated approach to testing of influenza A (Flu A), influenza B (Flu B) and respiratory syncytial virus (RSV) in one single assay.1
Information for Healthcare Professionals
Overview
Documents
Respiratory Testing & Patient-Specific Results
Respiratory viruses are responsible for a wide range of acute respiratory tract infections and represent a common cause of acute illness, including the common cold, influenza, and croup.1,2 Disease severity can be especially high in the young, the immunocompromised, and elderly patients.1
Increase Efficiency & Reduce Costs
Accurate and timely diagnosis of the cause of respiratory tract infections has a number of benefits for patients and their communities.
Reduces Complications
<!--td {border: 1px solid #cccccc;}br {mso-data-placement:same-cell;}--> Helps reduce the potential for further development of antimicrobial resistance due to antibiotics.2,3
Patient Care First
<!--td {border: 1px solid #cccccc;}br {mso-data-placement:same-cell;}--> Potential to improve patient care and helps decrease costs.2,3
Results with Purpose
<!--td {border: 1px solid #cccccc;}br {mso-data-placement:same-cell;}--> Provides valued information to public health authorities regarding which viruses are circulating in the community.2,4
Reduces Spread
<!--td {border: 1px solid #cccccc;}br {mso-data-placement:same-cell;}--> Assists infection control personnel to provide appropriate measures to reduce nosocomial spread.1,5
Simplify & Scale the Future of Diagnostics
The Panther Fusion Flu A/B/RSV Assay is part of the Hologic Molecular Scalable Solution, a portfolio combining a broad, high-performing assay menu with high-throughput automation. Designed to flexibly scale to meet your needs, from a single patient result to population-level screening.
Be Prepared for the Winter Respiratory Season
The Panther Fusion assay shows excellent clinical performance.1
98.8% Sensitivity
99.0% Specificity
Influenza A
100% Sensitivity
99.8% Specificity
Influenza B
99.3% Sensitivity
90.0% Specificity
RSV
Right Patient. Right Test. Right Time.6
- From true on-demand testing to high-throughput
- No sample batch constraints, prioritise urgent samples
- First results in 2.4 hours
- Run multiple assays from a single specimen tube at the same time
- Single dose, ready-to-use-assay reagent cartridge
- Long onboard stability of fluids and reagents
Verified Sample Collection
The Panther Fusion Flu A/B/RSV assay is validated for nasopharyngeal swabs in viral transport medium and universal transport medium.1
Insights
- Panther Fusion Flu A/B/RSV Assay [package insert]. AW-16162-001. San Diego, CA: Hologic, Inc.; 2022.
- Troeger C. et al GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018 Nov;18(11):1191-1210. doi: 10.1016/S1473-3099(18)30310-4. Epub 2018 Sep 19. PMID: 30243584; PMCID: PMC6202443.
- Pinsky BA, Hayden RT. Cost-Effective Respiratory Virus Testing. J Clin Microbiol. 2019 Aug 26;57(9):e00373-19. doi: 10.1128/JCM.00373-19. PMID: 31142607; PMCID: PMC6711893.
- WHO-2019-nCoV-Surveillance-Guidance-2022.1-eng.pdf https://www.who.int/publications/i/item/WHO-2019-nCoV-SurveillanceGuidance-2022.2 Accessed October, 2022.
- Lim RHF, Htun HL, Li AL, Guo H, Kyaw WM, Hein AA, Ang B, Chow A. Fending off Delta - Hospital measures to reduce nosocomial transmission of COVID-19. Int J Infect Dis. 2022 Apr;117:139-145. doi: 10.1016/j.ijid.2022.01.069. Epub 2022 Feb 4. PMID: 35124240; PMCID: PMC8813202.
- Panther/Panther Fusion System Operator´s Manual. AW-26055-001 Rev 001, San Diego, CA: Hologic Inc.; 2022.
Safety Data Sheets
Package Inserts
2797
Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium.
Notified Body number wherever applicable
EC Representative Information wherever applicable